ライフサイエンスコーパス: ASA

1 ASA >=3 (OR 2.87, 95%CI 1.56-5.26, p = 0.001) and estima

2 ASA at 1,000 muM enhances osteogenic potential of PDLSCs

3 ASA can undergo intramolecular cyclization, yielding an

4 ASA had equal effects on left ventricular outflow tract

5 ASA modulates the expression of growth factor-associated

6 ASA reduced UVB-induced 8-oxoguanine and cyclobutane pyr

7 ASA similarly reduced UVB-induced sunburn cells, 8-oxogu

8 ASA treatment increased levels of ASA-triggered lipoxin

9 ASA upregulated the expression of genes that could activ

10 ASA was the only As species detected in chicken feed sam

11 AAE (30.2%; 95% CI: 25.6%-34.3%; p<0.0001), ASA (37.9%; 95% CI: 29.2%-45.6%; p<0.0001), ARERs (25.6%

12 ran exposure (p < 0.0001), age (p < 0.0001), ASA use (p < 0.0003), and diabetes (p = 0.018) as signif

13 Patients were categorized into 3 groups: (1) ASA 81 mg+dipyridamole 75 mg daily (n = 26) with a targe

14 , whereas 66.9% of institutions performed 10 ASA procedures or fewer during the study period.

15 of 2 to 3 from June 2006 to August 2009; (2) ASA 81 mg daily (n = 18) from September 2009 to August 2

16 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was partially due to

17 2011 with a target INR of 1.5 to 2; and (3) ASA 325 mg daily from September 2011 to November 2014 wi

18 e anti-inflammatory 5-aminosalicylic acid (5-ASA) and one group untreated), with results showing sign

19 on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor ne

20 In general, women on 5-ASA, thiopurine, or anti-tumor necrosis factor (TNF) mon

21 moderate disease flare while on optimized 5-ASA or thiopurine therapy should be managed with systemi

22 iveness and tolerability of different oral 5-ASA therapies (sulfalsalazine vs diazo-bonded 5-ASAs vs

23 e effectiveness and tolerability of rectal 5-ASA and corticosteroid formulations in patients with dis

24 Oral and rectal 5-ASA are recommended first-line therapy for mild to moder

25 corticosteroid therapy, with transition to 5-ASA, thiopurine, anti-TNF (with or without thiopurine or

26 reported preoperative comorbidities (41.8%), ASA status (11.3%), and HIV status (7.8%), with a smalle

27 (NPs) that are deficient in arylsulfatase A (ASA) activity.

28 ery of the lysosomal enzyme arylsulfatase A (ASA).

29 patients undergoing alcohol septal ablation (ASA) and surgical septal myectomy (SM) with patient mana

30 the introduction of alcohol septal ablation (ASA) for the treatment of obstructive hypertrophic cardi

31 l myectomy (SM) and alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy have bee

32 and survival after alcohol septal ablation (ASA) in patient with hypertrophic cardiomyopathy.

33 complications after alcohol septal ablation (ASA) is unclear.

34 malic (MA), oxalic (OA), or acetylsalicylic (ASA) acid at three concentrations (1, 2 and 3mM) on the

35 Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with cor

36 cation test (DPT) with acetylsalicylic acid (ASA) during 2005-2012 (V1) were included (n=38).

37 new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events i

38 Acetylsalicylic acid (ASA) may serve as a potential therapeutic strategy to pr

39 apy, 25,458 (35%) with acetylsalicylic acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA

40 is study, we show that acetylsalicylic acid (ASA) treatment is able to significantly improve SHED-med

41 salicylic acid (SA) or acetylsalicylic acid (ASA) treatments during on-tree cherry growth and ripenin

42 care products (PPCPs) [acetylsalicylic acid (ASA), 2,5-dihydroxybenzoic acid (DBA), 2-phenylphenol (P

43 involves withdrawal of acetylsalicylic acid (ASA), or aspirin, while maintaining P2Y(12) inhibition.

44 ammatory drugs such as acetylsalicylic acid (ASA).

45 Since l-argininosuccinic acid (ASA) is the characteristic biomarker for the diagnosis o

46 he organoarsenic additives p-arsanilic acid (ASA), roxarsone (ROX) and nitarsone (NIT) in livestock f

47 activities of aspirin (acetylsalicylic acid [ASA]) could protect against UVB-induced DNA damage and s

48 tic enlargement: the "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis an

49 ACS, ASA, AWS, and SBAS presidents' CVs, at the time of their

50 Additionally, ASA-treated mice had reduced intravascular thrombin acti

51 ilure (6.2%, 7.6%, and 2.4%; P < .001) after ASA in higher-volume centers.

52 class (P=0.106), or syncope (P=0.426) after ASA.

53 dence of early conduction disturbances after ASA can be considered as a potentially safe management s

54 red with the SNIUAA and control groups after ASA administration.

55 baseline and at various time intervals after ASA administration.

56 e appropriate time to monitor patients after ASA is controversial.

57 remained a marker of reduced survival after ASA with a 5-fold increased risk of all-cause mortality

58 ) and ventricular tachyarrhythmia (VT) after ASA to better understand when patients can be safely dis

59 l outcome was assessed 0.6+/-0.6 years after ASA.

60 al status was obtained 7.9+/-4.0 years after ASA.

61 All ASA fusion proteins were enzymatically active and target

62 idespread use of amorphous aluminosilicates (ASA) in various industrial catalysts, the nature of the

63 ve shown that ginger constituents ameliorate ASA-induced gastric ulceration.

64 fasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budeso

65 ge (OR = 1.290, 95% CI: 1.101,1.511); and an ASA grade greater than 1 (OR = 2.920, 95% CI: 1.239, 6.8

66 cts clinical criteria for eligibility for an ASA challenge and/or desensitization.

67 hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable.

68 r indicates that for U.S. PLATO patients, an ASA dose >300 mg was not a significant interaction for v

69 tus [American Society of Anaesthesiologists (ASA) 4/5 vs 1, OR 0.29 (95% confidence interval, 95% CI

70 gher American Society of Anaesthesiologists [ASA] grade (RR for ASA grade 3-5 vs 1, 1.8 [1.6-2.1]), e

71 ts were American Society of Anaesthesiology (ASA) grade I.

72 tistics facilitates auditory-scene-analysis (ASA).

73 squares (PLS) and assigned signal analysis (ASA).

74 On multivariable analysis, ASA class 3 predicted a worse TO rate after PD (ASA 3 OR

75 Adjunctive omega-3 and ASA after periodontal debridement provides clinical and

76 ue mutants than predicted HSEbeta (0.37) and ASA (0.43).

77 in the average age in years of ACS (70) and ASA (66) presidents compared to the AWS (51) and SBAS (5

78 For the ACS and ASA cohort, 87% were male and 83% were White, collective

79 The ACS and ASA presidents' CVs displayed unsurpassed scholastic ach

80 achievements were comparable to the ACS (and ASA) cohort in 9 and 12 of the 15 accessed metrics, resp

81 Baseline models were CARES and ASA-PS.

82 Patient demographics and ASA use were assessed descriptively and as covariates.

83 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was partially due to the low-density

84 l was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

85 djustment for age, sex, body mass index, and ASA-performing center.

86 are independently associated with POMR, and ASA and case mix were not included, risk adjustment migh

87 pact of orally administered omega-3 PUFA and ASA as adjuncts to periodontal debridement for the treat

88 etermination of PPCPs in a sewage sample and ASA and FP in drug preparations.

89 eptal reduction therapy performed few SM and ASA procedures, which is below the threshold recommended

90 sed on tertiles of hospital volume of SM and ASA.

91 us, (2) quality of care measures: statin and ASA use, (3) healthcare resource utilization: emergency

92 In patients >/=75 years and ASA I-II, laparoscopic resection was associated with 46%

93 ified for age (<75 years or >/=75 years) and ASA status (I-II/III-IV).

94 were American Society of Anesthesiologists (ASA) >2, portal hypertension, intraoperative blood trans

95 were American Society of Anesthesiologists (ASA) class >=3, and 72% had a history of hepatic encepha

96 , and American Society of Anesthesiologists (ASA) classification (I/II/III; TVAE: 57.1%/41.8%/1.0% vs

97 igher American Society of Anesthesiologists (ASA) classification and postoperative complications.

98 , and American Society of Anesthesiologists (ASA) score.

99 sex, and American Society of Anesthesiology (ASA) score (difference in restricted mean survival time

100 ell culture model was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

101 diastole is that the atrial short-axis area (ASA) is smaller than the ventricular short-axis area (VS

102 s including solvent accessible surface area (ASA), residue depth (RD) and contact numbers (CN).

103 ortional to solvent-accessible surface area (ASA), whereas the HY values of alkanes depend on special

104 tations following ASA because, in this area, ASA still seems inferior to myectomy.

105 id-insoluble ash (AIA) and acid-soluble ash (ASA) fractions using HCl.

106 Aspirin (ASA) treatment significantly reduced lung platelet seque

107 Taking an aspirin (ASA) regularly after being diagnosed with colon cancer i

108 trations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emb

109 pholipids, which can be enhanced by aspirin (ASA) treatment.

110 y acids (omega-3 PUFA) and low-dose aspirin (ASA) have been proposed as a host modulation regimen to

111 of research suggests daily low-dose aspirin (ASA) reduces heart diseases and colorectal cancers.

112 reatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI,

113 to antiplatelet therapy, including aspirin (ASA) dosing, is uncertain.

114 rning to avoid maintenance doses of aspirin (ASA) >100 mg/daily.

115 s study investigates the effects of aspirin (ASA) on the proliferative capacity, osteogenic potential

116 There are limited data on aspirin (ASA) desensitization for patients with coronary artery d

117 ce daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as

118 urgeon (ACS), American Surgical Association (ASA), Association of Women Surgeons (AWS), and the Socie

119 istory of the American Surgical Association (ASA).

120 cerbation (AAE) or acute status asthmaticus (ASA).

121 he SC 59 and (SSN76)FC6608 RED KAFIR BAZINE (ASA N23) cultivars, which have an average RS content of

122 Severe septal hypertrophy before ASA remained a marker of reduced survival after ASA with

123 rated that the anatomical difference between ASA and VSA provides the basis for generating a hydrauli

124 Fusion proteins between ASA and the protein transduction domain of the human imm

125 ndings suggest that the relationship between ASA and VSA, and the associated hydraulic force, should

126 KA therapy was significantly higher for both ASA (IRR: 2.00; 95% CI: 1.88 to 2.12) and dual-therapy (

127 functions and canonic pathways activated by ASA treatment.

128 sk of small-intestinal enteropathy caused by ASA.

129 1 and the percentage of reactions induced by ASA/ibuprofen were significantly lower in Group A (P=.00

130 KH1-E mice prone to squamous cell carcinoma, ASA reduced plasma and skin prostaglandin E(2) levels an

131 The top 100 most cited ASA publications in the Annals of Surgery were identifie

132 of Anesthesiologists Physical Status Class (ASA).

133 They received enteric-coated ASA after ulcer healing.

134 operative variables (eg, age, comorbidities, ASA, wound classification), procedure type (eg, laparosc

135 stematically reviewing all studies comparing ASA with myectomy with long-term follow-up, (aborted) su

136 iving OAC are often treated with concomitant ASA, even when they do not have cardiovascular disease.

137 Improvement may be achieved by: 1) confining ASA to hypertrophic cardiomyopathy centers of excellence

138 ensitization, 253 patients (80.3%) continued ASA for at least 12 months.

139 nt tautomeric structure for the major cyclic ASA derivative, confirming the importance of intramolecu

140 ild-type mice and arylsulfatase A-deficient (ASA knockout) mice that accumulate sulfatides.

141 y, the strongest interaction is the diabetes-ASA interaction.

142 High-dose ASA in Heart Mate II patients treated concomitantly with

143 New users of low-dose ASA for secondary prevention of cardiovascular events, a

144 cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within the prior 3 years.

145 Low-dose ASA use within 24 hours of CABG is independently associa

146 m treatment with ticagrelor 60 mg + low-dose ASA yields a cost-effectiveness ratio suggesting interme

147 one, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA.

148 , or ticagrelor 90 mg twice daily + low-dose ASA.

149 f uncomplicated PUD in new users of low-dose ASA.

150 ertrophic cardiomyopathy referred for either ASA or SM from 2004 to 2015 were followed for the primar

151 Following ASA administration, LTE4 and 9alpha,11beta-PGF2 levels w

152 ntions and pacemaker implantations following ASA because, in this area, ASA still seems inferior to m

153 similar pattern eicosanoid levels following ASA challenge to those with NECD.

154 ity of Kupffer cells was preserved following ASA treatment.

155 For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was parti

156 4) use of appropriate amounts of alcohol for ASA.

157 in a BBB cell culture model was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II.

158 that GAS can be a therapeutic equivalent for ASA in inflammatory and proliferative diseases without t

159 ated risk of MI was significantly higher for ASA (incidence rate ratio [IRR]: 1.54; 95% confidence in

160 in delivery was, however, increased only for ASA-ApoE-II.

161 Guideline-based referral for ASA and SM leads to excellent outcomes with low procedur

162 ty of Anaesthesiologists [ASA] grade (RR for ASA grade 3-5 vs 1, 1.8 [1.6-2.1]), elevated body-mass i

163 The relative standard deviations (RSDs) for ASA, ROX and NIT determined from five measurements of th

164 ficant increase in lipid rafts isolated from ASA knockout mice.

165 reoperative comorbidities, hepatic function, ASA class, portal vein embolization rate)(p > 0.05).

166 Risk factors of age, gender, ASA (American Society of Anesthesiologists) grade, and s

167 ncept analysis of 75 heathy volunteers given ASA (300 mg) daily for 6 weeks, from July 31 through Oct

168 low preoperative albumin levels, and higher ASA (American Society of Anesthesiologists) status of th

169 perative pain, existing risk factors, higher ASA classification, higher BMI, and postoperative compli

170 Higher age, preoperative weight loss, higher ASA-score, higher N-stage, neoadjuvant chemotherapy, or

171 e older, more commonly presented with higher ASA scores, synchronous, multiple and smaller CRLM, unde

172 Among patients with successful in-hospital ASA desensitization, 253 patients (80.3%) continued ASA

173 0.3% and similarly low in both groups (0% in ASA and 0.8% in SM).

174 Association class I/II (96% in SM and 90% in ASA).

175 ciated with detergent-resistant membranes in ASA-deficient cells and showed a significant decrease in

176 These outcomes occur in ASA patients despite being an older cohort with signific

177 ion, and normalized the production of OLs in ASA-deficient NPs.

178 trongly associated with readmission included ASA class, albumin less than 3.5, diabetes, inpatient co

179 munosuppressants, smoking, active infection, ASA class, elective case, wound classification, and hist

180 heart rate, hemoglobin level, albumin level, ASA (American Society of Anesthesiologists) score, surgi

181 eral blood samples and activated with lysine ASA (LysASA).

182 Mechanistically, ASA treatment upregulates the telomerase reverse transcr

183 ega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (test

184 ega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2)

185 UVB-irradiated C57BL/6 mice receiving 0.4 mg ASA daily by gavage exhibited less inflammation, fewer s

186 pectively, when given high-dose (300-325 mg) ASA, regardless of treatment (clopidogrel or ticagrelor)

187 Therefore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulc

188 5% CI, 0.41-1.35; P = 0.33) compared with no ASA.

189 an one third of patients (39%) receiving OAC+ASA did not have a history of atherosclerotic disease, y

190 Patients receiving OAC+ASA were more likely to be male (66% versus 53%; P<0.000

191 e-1 blockade are increased in the absence of ASA.

192 strategy for targeted screening analysis of ASA and its cyclic forms using capillary electrophoresis

193 ent procedure for extraction and analysis of ASA, DBA, PP, and FP in these samples.

194 in reducing lysosomal storage in the CNS of ASA-knock-out mice treated by ERT.

195 Combination of ASA and VKA therapy was not associated with a lower risk

196 Discontinuation of ASA in the 62 patients (19.7%) who had responded to the

197 cking regarding optimal timing and dosing of ASA.

198 These effects of ASA, however, did not delay melanoma onset in TN(61R) mi

199 and transformation of the different forms of ASA have been studied and a strategy for targeted screen

200 centers including patients with a history of ASA sensitivity undergoing coronary angiography with int

201 A total of 330 patients with history of ASA sensitivity with known/suspected stable coronary art

202 ASA treatment increased levels of ASA-triggered lipoxin (ATL; 15-epi-lipoxin A4), and bloc

203 icantly reduced for patients taking 81 mg of ASA (1.4%) compared with 325 mg (2.9%) or none (3.9%).

204 ivariate analysis demonstrated that 81 mg of ASA decreased mortality risk by 66% (OR, 0.34; 95% CI, 0

205 CI, 0.18-0.66; P < 0.01), whereas 325 mg of ASA had no mortality benefit (OR, 0.74; 95% CI, 0.41-1.3

206 OYAGER PAD trial (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical L

207 .70), whereas being in the lowest tertile of ASA by volume was not independently associated with an i

208 he average-risk cohort included new users of ASA without a history of ulcers (n = 537).

209 Collection and analysis of data on ASA challenges and desensitizations from 10 allergy cent

210 an INR at event, 2.0), and in 38 patients on ASA 325 mg (54%; 1.4 events per patient year; mean INR a

211 Patients on ASA 325 mg had a higher adjusted hazard ratio of 2.9 (95

212 year; mean INR at event, 2.2), 4 patients on ASA 81 mg (22%; 0.38 events per patient year; mean INR a

213 Hemorrhagic events occurred in 6 patients on ASA 81 mg+dipyridamole (26%; 0.42 events per patient yea

214 Thus, preharvest treatments with SA or ASA could be promising tools to improve sweet cherry qua

215 Heart' and 'Sweet Late', were used and SA or ASA treatments, at 0.5, 1.0 and 2.0mM concentrations, we

216 all patients who were hospitalized for SM or ASA in a nationwide inpatient database from January 1, 2

217 to better describe the solvent exposure over ASA, CN and RD in many applications.

218 ent sources to facilitate active and passive ASA.

219 class 3 predicted a worse TO rate after PD (ASA 3 OR 0.59 [0.44-0.80]), whereas a dilated pancreatic

220 ch Council GLOBVAC Program and Bionor Pharma ASA.

221 ation of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing

222 ved with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0

223 y of ticagrelor alone versus ticagrelor plus ASA among high-risk patients undergoing PCI with drug-el

224 cagrelor plus placebo versus ticagrelor plus ASA following 3 months of dual antiplatelet therapy.

225 herapy is similar to that of ticagrelor plus ASA with respect to ex vivo blood thrombogenicity, where

226 g of CHB or sustained VT within 30 days post-ASA were assessed.

227 episode of CHB occurred within 24 hours post-ASA in 51 (21.0%) patients, between 24 and 48 hours in 3

228 of CHB or VT presenting after 72 hours post-ASA was low.

229 Preoperative ASA administration is associated with reduced morbidity

230 cording to the time of the last preoperative ASA dose: (1) 24 hours or less preoperatively (n = 1173)

231 periodontal debridement (CG), omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) afte

232 dement (test group [TG]1), or omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) befo

233 bo for TG1 and CG (t1), after omega-3 PUFA + ASA (before periodontal debridement) for TG2 (t1), and 6

234 r periodontal debridement and omega-3 PUFA + ASA or placebo for TG1 and CG (t1), after omega-3 PUFA +

235 rs or older, Asian or African American race, ASA (American Society of Anesthesiologists) class 3 or m

236 All patients underwent a rapid ASA (5.5 hours) desensitization procedure.

237 ce pretreated with ASA, or animals receiving ASA 3 hours postinfection, had significantly reduced pla

238 s was not standardised, and only NZ recorded ASA status and complete post-discharge mortality.

239 e sex, but not ethnicity, geographic region, ASA use, or clopidogrel use.

240 r after absorption to simultaneously release ASA and [6]-gingerol.

241 They resumed ASA after ulcer healing and H pylori eradication.

242 cute lung injury (TRALI), Boc2 also reversed ASA protection, and treatment with ATL in both LPS and T

243 of pyruvate and beta-aspartate semialdehyde (ASA) to form a cyclic product which dehydrates to form d

244 5% CI, 1.20, 18.50), adjusting for age, sex, ASA class, anesthesia type, inpatient status, portal hyp

245 Compared with SM, ASA patients were older ( P<0.001), had a higher burden

246 ciety of Anaesthesiologists-Physical Status (ASA-PS) in the prediction of 30-day postsurgical mortali

247 In volunteers, VSA was greater than ASA during 75-100% of diastole.

248 lower risk of first-time MI and stroke than ASA monotherapy.

249 These results indicate that ASA can protect against UVB-induced inflammation in skin

250 These data indicate that ASA treatment is a practical approach to improving SHED-

251 rt of the reason for this difference is that ASA is limited by the route of the septal perforators, w

252 Multivariate analysis showed that ASA within 24 hours preoperatively was associated with r

253 These findings suggest that ASA enhances PDLSC function and may be useful in regener

254 These results suggest that ASA may serve as a therapeutic approach to sepsis throug

255 ear dedicated to papers presented before the ASA Annual Meeting.

256 has served as the journal of record for the ASA since 1928, with a special issue each year dedicated

257 The top 100 most cited publications from the ASA are highly impactful, landmark studies representing

258 The 100 most cited papers from the ASA were published between 1955 and 2010 with an average

259 Major ions in the ASA fraction showed elevated accumulation rates of Ca, K

260 analogous physical model, (b) to measure the ASA and VSA throughout the cardiac cycle in healthy volu

261 In the ticagrelor-ASA >300 mg cohort, all-cause and vascular mortality wer

262 analysis, patients were grouped according to ASA dose: 81 mg (n = 1285), 325 mg (n = 1004), and none

263 of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular diseas

264 rium strain in healthy volunteers exposed to ASA.

265 ) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA,

266 fically, 119 subjects had index reactions to ASA doses lower than 300 mg.

267 ons; 86 of the latter had index reactions to ASA doses of 300 mg or less.

268 d histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, shoul

269 s of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable.

270 eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake.

271 ompetitive partial inhibitor with respect to ASA, and binds to all forms of the enzyme with a Ki near

272 At V2, the majority (24; 63.15%) tolerated ASA and other NSAIDs (Group A) while 14 (36.84%) still r

273 was significantly lower in patients who took ASA 24 hours or less preoperatively (1.5%) than in those

274 ApoE-II was also superior to wild-type ASA in reducing lysosomal storage in the CNS of ASA-knoc

275 In contrast to wild-type ASA, which is taken up by mannose-6-phosphate receptors,

276 .8%) underwent SM and 4862 (43.2%) underwent ASA.

277 severely symptomatic patients, 99 underwent ASA and 378 SM.

278 OMR for each site of age, admission urgency, ASA score, and procedure type.

279 2.9 (95% confidence interval, 1.2-7.0 versus ASA 81 mg+dipyridamole; P = 0.02) and 3.4 (95% confidenc

280 3.4 (95% confidence interval, 1.2-9.5 versus ASA 81 mg; P = 0.02) for hemorrhagic events.

281 varoxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0

282 apy and 8,962 (13%) with dual-therapy (VKA + ASA).

283 pendent predictors for 90-day mortality were ASA >2, Child-Pugh score B, BCLC stage B-C, and center's

284 lications were significantly associated with ASA 4/5 (OR, 3.84; 95% CI, 1.09, 13.57) and general anes

285 he primary end point was ulcer bleeding with ASA use in 5048 patient-years of follow-up evaluation.

286 sk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Out

287 Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg t

288 were prospectively re-evaluated by DPT with ASA/other NSAIDs at two time points between 2013 and 201

289 Rescue experiments with ASA showed a normalization of the ratio of long versus s

290 antiplatelet, and transfusion increased with ASA-anticoagulant (hazard ratio, 6.1; 95% confidence int

291 id desensitization protocol in patients with ASA sensitivity undergoing coronary angiography.

292 Mice pretreated with ASA, or animals receiving ASA 3 hours postinfection, had

293 Consecutive patients treated with ASA for hypertrophic cardiomyopathy from 2003 to 2019 at

294 y (age: 56+/-14 years, men 55%) treated with ASA.

295 ost reduction in patients over 75 years with ASA I-II undergoing colonic resection, and the largest c

296 cost increase in patients over 75 years with ASA III-IV undergoing rectal resection as compared with

297 paroscopy ranged from &OV0556;409 (<75 years ASA I-II) to &OV0556;1932 (>/=75 years ASA I-II).

298 l costs, ranging from &OV0556;501 (<75 years ASA I-II) to &OV0556;2515 (>/=75 years ASA III-IV).

299 years ASA I-II) to &OV0556;1932 (>/=75 years ASA I-II).

300 years ASA I-II) to &OV0556;2515 (>/=75 years ASA III-IV).